rct
2020
Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial
Unknown authors
Published in J Alzheimers Dis
Key Findings
Benfotiamine slowed cognitive decline numerically without significantly altering amyloid PET burden.
Conclusions
Amyloid endpoints were unchanged.
Outcomes Measured
Benfotiamine slowed cognitive decline numerically without significantly altering amyloid PET burden.
In preclinical models, benfotiamine efficiently ameliorates the clinical and biological pathologies that define Alzheimer's disease including ... increased advanced glycation end products (AGE), and inflammation.
Related Health Concerns
Study Details
Year:2020
Quality Score:6/10
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.